FFO (TTM)

FFO/share (TTM)

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Occupancy

Alexander’s, Inc. is a real estate investment trust (REIT) engaged in leasing, managing, developing and redeveloping properties. Alexander’s activities are conducted through its manager, Vornado Realty Trust. Alexander’s has seven properties in the greater New York City metropolitan area consisting of: 731 Lexington Avenue office and retail (including Bloomberg, L.P.'s world headquarters), the Rego Center complex in Rego Park, Queens, including the Rego Park I, II, and III retail properties and The Alexander apartment tower, and retail properties located in Paramus, NJ & Flushing, NY.

Alexander's Inc

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 3/15,
FFO/share Growth: 3/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details

ALX Oncology (ALXO) Expected to Announce Earnings on Friday

PARAMUS, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2025 today and reported:

Alexander's Announces Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open.

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

In trading on Wednesday, shares of Alexander's were yielding above the 8% mark based on its quarterly dividend (annualized to $18), with the stock changing hands as low as $224.25 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.

Alexander's Breaks Above 8% Yield Territory

PARAMUS, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 28, 2025 to stockholders of record on November 10, 2025.

Alexander's Declares Quarterly $4.50 Dividend on Common Shares

-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

KLP Kapitalforvaltning AS lessened its holdings in Alexander's, Inc. (NYSE: ALX) by 79.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 500 shares of the real estate investment trust's stock after selling 1,900 shares during the period. KLP Kapitalforvaltning AS's holdings in Alexander's were

KLP Kapitalforvaltning AS Lowers Position in Alexander’s, Inc. $ALX

PARAMUS, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2025 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 3, 2025, before the New York Stock Exchange opens.

Alexander's Announces Third Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer (CMO) on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology Board of Directors (BOD), where he previously served.

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York.

ALX Oncology to Participate in Upcoming Investor Conferences in September

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds upon body of positive preclinical data demonstrating dose dependent anti-tumor activity and favorable safety profile -Initial safety data anticipated in first half 2026 SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the"Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that the first patient has been dosed in the Company's Phase 1 clinical trial for ALX2004, a potential best- and first-in-class, epidermal growth factor receptor (EGFR) ADC that is being studied for the treatment of EGFR-expressing solid tumors.

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

SOUTH SAN FRANCISCO, CALIF., NOV. 07, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE.

ALX ONCOLOGY REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

PARAMUS, N.J., NOV. 03, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NEW YORK STOCK EXCHANGE: ALX) FILED ITS FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025 TODAY AND REPORTED:

ALEXANDER'S ANNOUNCES THIRD QUARTER FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE "COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED PLANS TO REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON FRIDAY, NOVEMBER 7TH, 2025, BEFORE MARKET OPEN.

ALX ONCOLOGY TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PIPELINE PROGRESS INCLUDING EVORPACEPT CD47 BIOMARKER DATA TO BE PRESENTED AT UPCOMING SITC ANNUAL MEETING

PARAMUS, N.J., OCT. 29, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A REGULAR QUARTERLY DIVIDEND OF $4.50 PER SHARE PAYABLE ON NOVEMBER 28, 2025 TO STOCKHOLDERS OF RECORD ON NOVEMBER 10, 2025.

ALEXANDER'S DECLARES QUARTERLY $4.50 DIVIDEND ON COMMON SHARES

-TWO POSTER PRESENTATIONS SHOWCASE BEST- AND FIRST-IN-CLASS POTENTIAL OF ALX2004, A NOVEL, ANTIBODY-DRUG CONJUGATE (ADC) FOR THE TREATMENT OF EGFR-EXPRESSING SOLID TUMORS

ALX ONCOLOGY ANNOUNCES PRECLINICAL DATA AND PHASE 1 TRIAL-IN-PROGRESS PRESENTATIONS OF ALX2004, A NOVEL EGFR-TARGETED ADC, AT 2025 AACR-NCI-EORTC CONFERENCE

PARAMUS, N.J., OCT. 21, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT WILL FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025 WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND ISSUE ITS THIRD QUARTER EARNINGS RELEASE ON MONDAY, NOVEMBER 3, 2025, BEFORE THE NEW YORK STOCK EXCHANGE OPENS.

ALEXANDER'S ANNOUNCES THIRD QUARTER EARNINGS RELEASE DATE AND VORNADO REALTY TRUST QUARTERLY CONFERENCE CALL

SOUTH SAN FRANCISCO, CALIF., SEPT. 12, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THE APPOINTMENT OF DR. KLENCKE TO THE ROLE OF INTERIM CHIEF MEDICAL OFFICER (CMO) ON A FULL-TIME BASIS. DR. ALAN SANDLER IS DEPARTING FROM THE ROLE OF CMO AND WILL RETURN TO HIS FORMER POSITION ON THE ALX ONCOLOGY BOARD OF DIRECTORS (BOD), WHERE HE PREVIOUSLY SERVED.

ALX ONCOLOGY APPOINTS BOARD MEMBER BARBARA KLENCKE, M.D., AS INTERIM CHIEF MEDICAL OFFICER

SOUTH SAN FRANCISCO, CALIF., AUG. 29, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE "COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT ALX ONCOLOGY LEADERSHIP WILL PARTICIPATE IN BOTH THE CANTOR GLOBAL HEALTHCARE CONFERENCE 2025 AND H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK.

ALX ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN SEPTEMBER

- A POTENTIAL BEST- AND FIRST-IN-CLASS ANTIBODY-DRUG CONJUGATE (ADC) FOR THE TREATMENT OF EGFR-EXPRESSING SOLID TUMORS, ALX2004 IS UNIQUELY DESIGNED WITH EVERY COMPONENT OPTIMIZED TO MAXIMIZE THE THERAPEUTIC WINDOW -FIRST-IN-HUMAN TRIAL OF ALX2004 BUILDS UPON BODY OF POSITIVE PRECLINICAL DATA DEMONSTRATING DOSE DEPENDENT ANTI-TUMOR ACTIVITY AND FAVORABLE SAFETY PROFILE -INITIAL SAFETY DATA ANTICIPATED IN FIRST HALF 2026 SOUTH SAN FRANCISCO, CALIF., AUG. 19, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE"COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE COMPANY'S PHASE 1 CLINICAL TRIAL FOR ALX2004, A POTENTIAL BEST- AND FIRST-IN-CLASS, EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ADC THAT IS BEING STUDIED FOR THE TREATMENT OF EGFR-EXPRESSING SOLID TUMORS.

ALX ONCOLOGY DOSES FIRST PATIENT IN PHASE 1 DOSE ESCALATION TRIAL EVALUATING ADC ALX2004 FOR THE TREATMENT OF EGFR-EXPRESSING SOLID TUMORS

 DATA FROM ASPEN-06 TRIAL HIGHLIGHTS CD47 EXPRESSION AS A KEY PREDICTIVE BIOMARKER OF GREATER RESPONSE TO EVORPACEPT IN HER2+ GASTRIC CANCER; UPDATED DATA TO BE PRESENTED AT A MEDICAL CONFERENCE IN Q4 2025

ALX ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

SOUTH SAN FRANCISCO, CALIF., AUG. 05, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE "COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED PLANS TO REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND A BUSINESS UPDATE ON TUESDAY, AUGUST 12TH, 2025, AFTER MARKET CLOSE.

ALX ONCOLOGY TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 12, 2025

PARAMUS, N.J., AUG. 04, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NEW YORK STOCK EXCHANGE: ALX) FILED ITS FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2025 TODAY AND REPORTED:

Alexander's Inc

ALX

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX